MX2021012221A - Inhibidor del cd73, metodo de preparacion y aplicacion del mismo. - Google Patents
Inhibidor del cd73, metodo de preparacion y aplicacion del mismo.Info
- Publication number
- MX2021012221A MX2021012221A MX2021012221A MX2021012221A MX2021012221A MX 2021012221 A MX2021012221 A MX 2021012221A MX 2021012221 A MX2021012221 A MX 2021012221A MX 2021012221 A MX2021012221 A MX 2021012221A MX 2021012221 A MX2021012221 A MX 2021012221A
- Authority
- MX
- Mexico
- Prior art keywords
- cancer
- preparation
- inhibitor
- drugs
- application
- Prior art date
Links
- 229940127272 CD73 inhibitor Drugs 0.000 title abstract 3
- 238000002360 preparation method Methods 0.000 title abstract 3
- 239000003814 drug Substances 0.000 abstract 3
- 229940079593 drug Drugs 0.000 abstract 3
- 208000023275 Autoimmune disease Diseases 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 2
- 102100022464 5'-nucleotidase Human genes 0.000 abstract 1
- 208000003174 Brain Neoplasms Diseases 0.000 abstract 1
- 206010006187 Breast cancer Diseases 0.000 abstract 1
- 208000026310 Breast neoplasm Diseases 0.000 abstract 1
- 206010009944 Colon cancer Diseases 0.000 abstract 1
- 101000678236 Homo sapiens 5'-nucleotidase Proteins 0.000 abstract 1
- 208000007766 Kaposi sarcoma Diseases 0.000 abstract 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 abstract 1
- 206010025323 Lymphomas Diseases 0.000 abstract 1
- 206010033128 Ovarian cancer Diseases 0.000 abstract 1
- 206010061535 Ovarian neoplasm Diseases 0.000 abstract 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 abstract 1
- 206010060862 Prostate cancer Diseases 0.000 abstract 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 abstract 1
- 208000029742 colonic neoplasm Diseases 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 208000032839 leukemia Diseases 0.000 abstract 1
- 201000005202 lung cancer Diseases 0.000 abstract 1
- 208000020816 lung neoplasm Diseases 0.000 abstract 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 201000001441 melanoma Diseases 0.000 abstract 1
- 208000030159 metabolic disease Diseases 0.000 abstract 1
- 201000002528 pancreatic cancer Diseases 0.000 abstract 1
- 208000008443 pancreatic carcinoma Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/16—Purine radicals
- C07H19/20—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
- C07H19/207—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids the phosphoric or polyphosphoric acids being esterified by a further hydroxylic compound, e.g. flavine adenine dinucleotide or nicotinamide-adenine dinucleotide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H1/00—Processes for the preparation of sugar derivatives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H1/00—Processes for the preparation of sugar derivatives
- C07H1/02—Phosphorylation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/23—Heterocyclic radicals containing two or more heterocyclic rings condensed among themselves or condensed with a common carbocyclic ring system, not provided for in groups C07H19/14 - C07H19/22
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Rheumatology (AREA)
- Biomedical Technology (AREA)
- Physical Education & Sports Medicine (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Cardiology (AREA)
- Pulmonology (AREA)
- Heart & Thoracic Surgery (AREA)
- Oncology (AREA)
- Dermatology (AREA)
- Hospice & Palliative Care (AREA)
- Urology & Nephrology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Communicable Diseases (AREA)
- Vascular Medicine (AREA)
- Hematology (AREA)
- Pain & Pain Management (AREA)
Abstract
Un inhibidor del CD73 que tiene la estructura representada por la fórmula (I), un método de preparación para el mismo y una aplicación del mismo. La serie de compuestos puede aplicarse de forma amplia en la preparación de fármacos para el tratamiento de cánceres o tumores mediados al menos parcialmente por el CD73, enfermedades y trastornos autoinmunes y enfermedades metabólicas, en especial fármacos para el tratamiento del melanoma, cáncer de colon, cáncer de páncreas, cáncer de mama, cáncer de próstata, cáncer de pulmón, leucemia, tumor cerebral, linfoma, cáncer de ovario y sarcoma de Kaposi. Se espera que se desarrolle una nueva generación de fármacos inhibidores del CD73.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910350348 | 2019-04-28 | ||
| CN201910510367 | 2019-06-13 | ||
| CN201911375322 | 2019-12-27 | ||
| PCT/CN2020/087259 WO2020221209A1 (zh) | 2019-04-28 | 2020-04-27 | 一种cd73抑制剂，其制备方法和应用 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2021012221A true MX2021012221A (es) | 2021-11-03 |
Family
ID=73029432
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2021012221A MX2021012221A (es) | 2019-04-28 | 2020-04-27 | Inhibidor del cd73, metodo de preparacion y aplicacion del mismo. |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20220162253A1 (es) |
| EP (2) | EP3964518A4 (es) |
| JP (3) | JP2022526147A (es) |
| KR (1) | KR102653823B1 (es) |
| CN (2) | CN116715700A (es) |
| AU (1) | AU2020264642B2 (es) |
| BR (1) | BR112021019887A2 (es) |
| CA (1) | CA3130253C (es) |
| MX (1) | MX2021012221A (es) |
| TW (1) | TWI821559B (es) |
| WO (1) | WO2020221209A1 (es) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3207590A1 (en) * | 2021-02-08 | 2022-08-11 | Xuejun Zhang | Pyridopyrimidinone derivative, preparation method therefor, and use thereof |
| AU2023252914A1 (en) | 2022-04-13 | 2024-10-17 | Arcus Biosciences, Inc. | Combination therapy for treating trop-2 expressing cancers |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20180100638A (ko) * | 2016-01-08 | 2018-09-11 | 아르커스 바이오사이언시즈 인코포레이티드 | 5'-뉴클레오티다아제, 엑토의 조절제, 및 이의 용도 |
| DE102016011946A1 (de) * | 2016-08-09 | 2018-02-15 | Xenios Ag | Oxygenator mit einer Gehäusewandung |
| WO2018067424A1 (en) * | 2016-10-03 | 2018-04-12 | Arcus Biosciences, Inc. | Inhibitors of adenosine 5'-nucleotidase |
| WO2018208727A1 (en) * | 2017-05-08 | 2018-11-15 | Eternity Bioscience Inc. | Nucleoside and nucleotide analogues as cd73 inhibitors and therapeutic uses thereof |
| US11129841B2 (en) * | 2017-05-10 | 2021-09-28 | Oric Pharmaceuticals, Inc. | CD73 inhibitors |
| CN111094317B (zh) * | 2017-12-29 | 2023-03-31 | 上海和誉生物医药科技有限公司 | 一种具有cd73抑制活性的膦酸衍生物、其制备方法和应用 |
| JP7417530B2 (ja) * | 2018-03-09 | 2024-01-18 | アーカス バイオサイエンシズ インコーポレイティド | 優先投与される免疫増強薬 |
| TW202017569A (zh) * | 2018-05-31 | 2020-05-16 | 美商佩樂敦治療公司 | 用於抑制cd73之組合物及方法 |
| WO2019246403A1 (en) * | 2018-06-21 | 2019-12-26 | Calithera Biosciences, Inc. | Ectonucleotidase inhibitors and methods of use thereof |
| CN110885352B (zh) * | 2018-09-11 | 2023-02-24 | 润佳（苏州）医药科技有限公司 | Cd73抑制剂及其药学应用 |
| WO2020185859A1 (en) * | 2019-03-12 | 2020-09-17 | Arcus Biosciences, Inc. | Treatment of oncogene-driven cancers |
| AU2020256098A1 (en) * | 2019-03-29 | 2021-10-28 | Arcus Biosciences, Inc. | Treatment of cancer utilizing an identified adenosine fingerprint |
| WO2020210970A1 (en) * | 2019-04-16 | 2020-10-22 | Bioardis Llc | Imidazotriazine derivatives as cd73 inhibitors |
-
2020
- 2020-04-23 TW TW109113624A patent/TWI821559B/zh active
- 2020-04-27 MX MX2021012221A patent/MX2021012221A/es unknown
- 2020-04-27 CN CN202310677088.XA patent/CN116715700A/zh active Pending
- 2020-04-27 EP EP20798596.1A patent/EP3964518A4/en active Pending
- 2020-04-27 BR BR112021019887A patent/BR112021019887A2/pt unknown
- 2020-04-27 US US17/438,770 patent/US20220162253A1/en active Pending
- 2020-04-27 EP EP23196737.3A patent/EP4272836A3/en active Pending
- 2020-04-27 KR KR1020217028340A patent/KR102653823B1/ko active IP Right Grant
- 2020-04-27 JP JP2021556880A patent/JP2022526147A/ja active Pending
- 2020-04-27 CN CN202080010129.4A patent/CN113366008B/zh active Active
- 2020-04-27 AU AU2020264642A patent/AU2020264642B2/en active Active
- 2020-04-27 CA CA3130253A patent/CA3130253C/en active Active
- 2020-04-27 WO PCT/CN2020/087259 patent/WO2020221209A1/zh unknown
-
2023
- 2023-07-18 JP JP2023116962A patent/JP2023145547A/ja active Pending
- 2023-07-18 JP JP2023116963A patent/JP2023145548A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2020264642B2 (en) | 2023-05-25 |
| US20220162253A1 (en) | 2022-05-26 |
| EP4272836A2 (en) | 2023-11-08 |
| AU2020264642A1 (en) | 2021-09-02 |
| CA3130253C (en) | 2023-07-18 |
| TWI821559B (zh) | 2023-11-11 |
| WO2020221209A1 (zh) | 2020-11-05 |
| JP2022526147A (ja) | 2022-05-23 |
| EP3964518A4 (en) | 2023-05-17 |
| CN116715700A (zh) | 2023-09-08 |
| BR112021019887A2 (pt) | 2022-01-18 |
| JP2023145548A (ja) | 2023-10-11 |
| CN113366008A (zh) | 2021-09-07 |
| KR20210126051A (ko) | 2021-10-19 |
| CN113366008B (zh) | 2023-06-23 |
| EP3964518A1 (en) | 2022-03-09 |
| CA3130253A1 (en) | 2020-11-05 |
| JP2023145547A (ja) | 2023-10-11 |
| KR102653823B1 (ko) | 2024-04-02 |
| EP4272836A3 (en) | 2023-11-22 |
| TW202106311A (zh) | 2021-02-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12019501029A1 (en) | Fgfr4 inhibitor, preparation method therefor and pharmaceutical use therefor | |
| HRP20010892A2 (en) | 6-alkenyl-, 6-alkinyl- and 6-epoxy-epothilone derivatives, process for their production, and their use in pharmaceutical preparations | |
| MX2022008456A (es) | Inhibidores de mek y usos terapeuticos de estos. | |
| MX2022005780A (es) | Moduladores de receptores estrogenicos. | |
| MX2021012221A (es) | Inhibidor del cd73, metodo de preparacion y aplicacion del mismo. | |
| PH12018502572A1 (en) | 1-tetrahydropyranylcarbonyl-2,3-dihydro-1h-indole compounds for treating cancer | |
| MX2018011992A (es) | Compuestos de aminopurina sustituida, composiciones de estos y metodos de tratamiento con estos. | |
| IL127946A0 (en) | Apoptosis inducing adamantyl derivatives and their usage as anti-cancer agents | |
| EA201890730A1 (ru) | Производные пиразолопиримидина в качестве ингибиторов btk для лечения злокачественного новообразования | |
| MX2022005775A (es) | Compuestos terapeuticos y metodos de uso. | |
| RU2014108042A (ru) | Фармацевтическая композиция для лечения и профилактики злокачественной опухоли | |
| MX2021008094A (es) | Metodos y composiciones para el tratamiento del cancer. | |
| ZA202100485B (en) | Pyrimidine compounds and pharmaceutical compositions for preventing or treating cancers including the same | |
| EA202092113A1 (ru) | Способ получения модуляторов p300 и/или cbp | |
| MX2022008099A (es) | Tratamiento para el cancer con inhibidores de cdk12/13. | |
| MX2022000550A (es) | Imidazopirimidinas como inhibidores de eed y uso de estas. | |
| MX2020012291A (es) | Compuestos para el tratamiento de cancer de mama triple negativo y cancer de ovario. | |
| MX2021000043A (es) | Activadores de la respuesta a proteinas desplegadas. | |
| MX2022000853A (es) | Anticuerpos anti-liv1 humanizados para el tratamiento de cancer. | |
| MX2017014145A (es) | Moduladores selectivos de la actividad del receptor gpr55: derivados de cromenopirazol. | |
| NZ595490A (en) | Derivatives of kahalalide F for the treatment of cancer | |
| MX2024001424A (es) | Compuesto radiomarcado y uso del mismo. | |
| MX2022005445A (es) | Tratamientos contra el cáncer dirigidos a las células madre cancerosas. | |
| MX2023006434A (es) | Inhibidores de quinasa y usos de los mismos. | |
| MX2023009962A (es) | Composicion farmaceutica combinada que contiene inhibidor de cdk4/6 y su uso. |